Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial. (PubMed, Lancet Respir Med) - Mar 25, 2026 - P2 | "Poractant alfa, administered endotracheally to infants with early critical bronchiolitis, although safe, did not reduce the duration of IMV compared with the sham intervention. Therefore, our findings suggest that it should not be used for this indication at this dose and administration method."
Journal • P2 data • Critical care • Pediatrics • Pulmonary Disease • Respiratory Diseases
|
|
; Ahmed Osman; Annmarie Wherton-Whitehurst; Anthony D Postle; Ashley P Jones; Blessing Osaghae; Carly Vaughan; Carrol Gamble; Catrin Barker; Chloe Donohue; Clare Fowler; Constantinos Kanaris; Edgar Brincat; Elisabeth Day; Elizabeth Deja; Evette Allen; Gerri Sefton; Howard W Clark; James Weitz; Jane V Cassidy; Jens Madsen; John Pappachan; Julie Richardson; Kentigern Thorburn; Kerry Woolfall; Kevin P Morris; Laura Price; Lynsey Finnetty; Malcolm G Semple; Mark A Turner; Matthew Peak; Patrick E Davies; Paul C Ritson; Paul S McNamara; Peter J Davis; Rachael Cooper; Rachel S Agbeko; Richard Levin; Santosh Sundararajan; Simona Lampariello; Stephen D Playfor; Tracy Moitt; Tsz-Yan Milly Lo
|